

Infirst Healthcare Group demerges to accelerate growth of its businesses

Infirst Healthcare Limited, a privately-owned UK healthcare company focused on improving existing medicines, today announces that it has demerged into three separate companies in order to accelerate growth of these separate businesses:

- Flarin Holdings Limited
- Infirst Healthcare Inc
- Infirst Healthcare Limited

Each company will have its own management and commercial focus:

Flarin Holdings Limited

A new company Flarin Holdings Limited, and its 100% subsidiary infirst Ltd, will exclusively focus on the rapid commercialisation and globalisation of Flarin (patent protected lipid formulation of ibuprofen).

- Flarin is a unique and patent protected lipid formulated ibuprofen which at a dose of 1200 mg/day has shown to be as effective as 2400mg/day of standard liquid ibuprofen capsules in patients with acute joint pain 1. Flarin's unique lipid formulation also helps to shield the stomach from damage 2 .
- Flarin Holdings Limited will shortly close the first of two planned rounds of fundraising in order to accelerate the commercial development of Flarin for relief from joint pain and inflammation.
- Flarin Holdings Limited and infirst Limited will be run by Andrew Macmillen who had a 27-year career with GlaxoSmithKline with general management and regional leadership roles in Latin America as well as Europe. Andrew also brings comprehensive business development experience to this role.

Infirst Healthcare Inc.

Infirst Healthcare Inc., founded in 2013 and based in Westport, CT, will continue as an independent USA enterprise directly owned by the current Infirst Healthcare Limited shareholders.

- Infirst Healthcare Inc. is a fast-growing and highly efficient marketing and sales organisation with integrated R&D and supply capabilities in the USA.
- Infirst Healthcare Inc. markets leading iconic consumer brands such as Mylanta® antacids and Mylicon® paediatric stomach remedies and will continue to be led by James Barickman, its current president and CEO.

Infirst Healthcare Limited

- Infirst Healthcare Limited will focus on the development and commercialisation of its IP estate in the areas of respiratory conditions as well as lipid platform technology (excluding Flarin and NSAID related utility for human medicinal use).



- Manfred Scheske will continue to manage Infirst Healthcare Ltd. Manfred will also serve as Chairman of the Boards of Infirst Healthcare Inc. as well as Flarin Holdings Limited.

“This demerger is an important step to attract more specialised investors and partners and to further accelerate growth for the unique businesses which Infirst Healthcare Limited has started,” commented Manfred Scheske. “Although independently owned, the three businesses will continue to use the ‘infirst’ name in their operating entities and will carry the spirit of ‘Known Drugs – Made Better’ to new horizons.”

Media enquiries:

andrew.macmillen@infirst.co.uk +44 (0) 207 153 6600

manfred.scheske@infirst.co.uk +44 (0) 207 153 6600

james.barickman@infirst-usa.com +1 203 222 1300

1 Bierma- Zeinstra SMA, Conaghan PG, Brew J et al. Osteoarthr Cartil: 2017 25; 12: 1942–1951

Open Access: <http://dx.doi.org/10.1016/j.joca.2017.09.002> Accessed at:

[http://www.oarsijournal.com/article/S1063-4584\(17\)31197-4/fulltext](http://www.oarsijournal.com/article/S1063-4584(17)31197-4/fulltext)

2 Data on file, Infirst Healthcare Limited.

www.flarin.co.uk

<https://www.linkedin.com/company/flarin/>